Brief: 4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy
10/03/2025 13:31
March 10 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O: 4DMT ANNOUNCES FIRST PATIENTS ENROLLED IN 4FRONT-1 PHASE 3 CLINICAL TRIAL EVALUATING 4D-150 IN WET AMD 4D MOLECULAR THERAPEUTICS INC - 4FRONT-2 TRIAL EXPECTED TO INITIATE IN Q3 2025 Source text: nGNX9DC81n Further company coverage: FDMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings